Inhibition of 11β‐Hydroxysteroid dehydrogenase‐1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double‐blind, placebo‐controlled, phase II study
Yadav Y, Dunagan K, Khot R, Venkatesh S, Port J, Galderisi A, Cobelli C, Wegner C, Basu A, Carter R, Basu R. Inhibition of 11β‐Hydroxysteroid dehydrogenase‐1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double‐blind, placebo‐controlled, phase II study. Diabetes Obesity And Metabolism 2022, 24: 881-890. PMID: 35014156, PMCID: PMC9135169, DOI: 10.1111/dom.14646.Peer-Reviewed Original ResearchMeSH Keywords11-beta-Hydroxysteroid Dehydrogenase Type 1Diabetes Mellitus, Type 2Double-Blind MethodHumansLiverNiacinamideNon-alcoholic Fatty Liver DiseasePiperidinesConceptsNonalcoholic fatty liver diseaseLiver fat fractionFatty liver diseaseMagnetic resonance imagingMean changePlacebo groupPrimary outcomeLiver diseasePresence of NAFLDSignificant between-group differencesPhase II studyPhase 2 studyKey inclusion criteriaType 2 diabetesBetween-group differencesShort-term treatmentBiopsy positiveII studyNonalcoholic steatohepatitisWeek 12Liver steatosisHepatic fatInsulin sensitivityAZD4017Liver enzymes